Cargando…

Drugging PI3K in cancer: refining targets and therapeutic strategies

The phosphatidylinositol-3 kinase (PI3K) pathway is one of the most frequently activated pathogenic signalling routes in human cancers, making it a rational and important target for innovative anticancer drug development and precision medicine. The three main classes of PI3K inhibitors currently in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yap, Timothy A, Bjerke, Lynn, Clarke, Paul A, Workman, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science Ltd 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728196/ https://www.ncbi.nlm.nih.gov/pubmed/26117819 http://dx.doi.org/10.1016/j.coph.2015.05.016

Ejemplares similares

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia
por: Blunt, Matthew D., et al.
Publicado: (2015)

Development of targeted therapeutic strategies and refinement of sperm DNA fragmentation testing
por: Agarwal, Ashok, et al.
Publicado: (2017)

The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors
por: Rogers, Hazel A., et al.
Publicado: (2016)

Targeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in COVID-19 patients
por: Abu-Eid, Rasha, et al.
Publicado: (2021)

Targeting PI3K by Natural Products: A Potential Therapeutic Strategy for Attention-deficit Hyperactivity Disorder
por: Noori, Tayebeh, et al.
Publicado: (2022)

Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy
por: Agliano, Alice, et al.
Publicado: (2017)

In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells
por: Al-Saffar, Nada M. S., et al.
Publicado: (2017)

Therapeutic targets for cancer: Current concepts with PI 3-K, Akt, & mTOR
por: Maiese, Kenneth
Publicado: (2013)

PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19
por: Palma, Giuseppe, et al.
Publicado: (2020)

Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
por: Chandrasekaran, Sanjay, et al.
Publicado: (2021)

PI3K inhibitors: review and new strategies
por: Zhang, Mingzhen, et al.
Publicado: (2020)

Lactate and Choline Metabolites Detected In Vitro by Nuclear Magnetic Resonance Spectroscopy Are Potential Metabolic Biomarkers for PI3K Inhibition in Pediatric Glioblastoma
por: Al-Saffar, Nada M. S., et al.
Publicado: (2014)

Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities
por: Hubbard, Paul A., et al.
Publicado: (2014)

Discovery of small molecule cancer drugs: Successes, challenges and opportunities
por: Hoelder, Swen, et al.
Publicado: (2012)

Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
por: Chen, Dongshao, et al.
Publicado: (2018)

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
por: Dolly, Saoirse O, et al.
Publicado: (2017)

Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
por: Shuttleworth, S.J, et al.
Publicado: (2011)

Functional redundancy of PI3K isoforms in conventional T cells provides a selective Treg-targeting strategy through inhibition of PI3K-delta isoform
por: Ahmad, Shamim, et al.
Publicado: (2014)

Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma
por: Tessiri, Supharada, et al.
Publicado: (2022)

Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma
por: Barzegar Behrooz, Amir, et al.
Publicado: (2022)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics
por: Josephs, Debra H., et al.
Publicado: (2016)

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
por: Mezynski, M. Janusz, et al.
Publicado: (2021)

Combining TRAIL with PI3 Kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling
por: Saturno, Grazia, et al.
Publicado: (2013)

Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells
por: TIAN, FENG, et al.
Publicado: (2015)

Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells
por: Tian, Feng, et al.
Publicado: (2023)

Targeting EGFR and PI3K pathways in ovarian cancer
por: Glaysher, S, et al.
Publicado: (2013)

PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells
por: Mangiapane, Laura Rosa, et al.
Publicado: (2022)

Screening of PI3K-Akt-targeting Drugs for Silkworm against Bombyx mori Nucleopolyhedrovirus
por: Wang, Bingbing, et al.
Publicado: (2019)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Determination of the branching ratios $\Gamma(K_{L} \to 3\pi^{0}) / \Gamma(K_{L} \to \pi^{+}\pi^{-}\pi^{0})$ and $\Gamma(K_{L} \to 3\pi^{0}) / \Gamma(K_{L} \to \pi e\nu)$
por: Kreutz, A., et al.
Publicado: (1994)

Targeting the PI3K/Akt signaling pathway in pancreatic β‐cells to enhance their survival and function: An emerging therapeutic strategy for type 1 diabetes
por: Camaya, Inah, et al.
Publicado: (2022)

Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway
por: Presneau, N, et al.
Publicado: (2009)

Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart
por: Klement, Giannoula L., et al.
Publicado: (2012)

Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer
por: Conway, James R.W., et al.
Publicado: (2018)

PI3K mutations in breast cancer: prognostic and therapeutic implications
por: Mukohara, Toru
Publicado: (2015)

The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases
por: Banham-Hall, Edward, et al.
Publicado: (2012)

Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer
por: Hashemzadeh, Kamelia, et al.
Publicado: (2019)

Endometrial Cancer as a Metabolic Disease with Dysregulated PI3K Signaling: Shedding Light on Novel Therapeutic Strategies
por: Kyo, Satoru, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o854vh74np0he4rj6teepsklsi